Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542148 | 0.86 | MAOB (0.55) | MAOBCYP3A4MAPTESR1ESR2 | |
| SCHEMBL9862160 | 0.86 | MAOB (0.55) | MAOBCYP3A4MAPTESR1ESR2 | |
| SCHEMBL4363954 | 0.84 | MAOB (0.53) | MAOBCYP3A4MAPTESR1ESR2 | |
| SCHEMBL2041131 | 0.83 | MAOB (0.52) | MAOBCYP3A4ESR1ESR2GAA | |
| SCHEMBL18535801 | 0.83 | MAOB (0.57) | MAOBCYP3A4MAPTESR1ESR2 | |
| SCHEMBL10750457 | 0.81 | MAOB (0.50) | MAOBCYP3A4MAPTESR1ESR2 | |
| SCHEMBL26085067 | 0.81 | MAOB (0.50) | MAOBCYP3A4MAPTESR1ESR2 | |
| SCHEMBL25255901 | 0.80 | PTGS2 (0.50) | MAOBCYP3A4MAPTAPP | |
| SCHEMBL21524722 | 0.78 | MAOB (0.47) | MAOBCYP3A4MAPTESR1ESR2 | |
| SCHEMBL20821061 | 0.78 | MAOB (0.47) | MAOBCYP3A4MAPTESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851102-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020154350-A1 | IMIDAZO[1,5-A]PYRIDINE, 1,2,4-TRIAZOLO[4,3-A]PYRIDINE AND IMIDAZO[1,5-A]PYRAZINE AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200231590-A1 | IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| US-20090181994-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181994-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504402-B2 | Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7323567-B2 | RSV polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-01-29 | — | — | US | disclosed |
| US-20070225317-A1 | RSV POLYMERASE INHIBITORS | SIMONEAU BRUNO | 2007-09-27 | — | — | US | disclosed |
| US-7084194-B2 | Halogen-free resin composition | CHANG CHUN PLASTICS CO., LTD. (TW) | 2006-08-01 | — | — | US | disclosed |
| US-6900269-B2 | Halogen-free resin composition | CHANG CHUN PLASTICS CO., LTD. (TW) | 2005-05-31 | — | — | US | disclosed |
| US-20040254305-A1 | Epoxy resin composition for photosemiconductor package | CHANG CHUN PLASTIC CO., LTD. (TW) | 2004-12-16 | — | — | US | disclosed |
| US-20040158023-A1 | Halogen-free resin composition | CHANG CHUN PLASTICS CO., LTD. (TW) | 2004-08-12 | — | — | US | disclosed |
| US-20040147640-A1 | Halogen-free resin composition | CHANG CHUN PLASTICS CO., LTD. (TW) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851102-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | JAK3, JAK1, JAK2 | MAOB 3254/4885CYP3A4 514/4885MAPT 2399/4885 |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | MAOB 2826/4885CYP3A4 2836/4885MAPT 2611/4885 |
| US-20070225317-A1 | RSV POLYMERASE INHIBITORS | POLR2E, POLR2H, POLR2A | MAOB 2566/4885CYP3A4 2628/4885MAPT 3709/4885 |
| US-20200231590-A1 | IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | MAOB 3254/4885CYP3A4 514/4885MAPT 2399/4885 |
| US-20090181994-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | HSD11B1, HSD17B1, HSD3B1 | MAOB 1498/4885CYP3A4 106/4885MAPT 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.